Roivant Sciences (ROIV) Share-based Compensation (2020 - 2025)
Roivant Sciences (ROIV) posted Share-based Compensation of $269.0 million for Q4 2025, up 279.8% on a QoQ basis from $70.8 million in Q3 2025, and up 30.87% year-over-year from $205.5 million in Q4 2024.
Roivant Sciences (ROIV) Share-based Compensation (2020 - 2025) Analysis & Trends
Roivant Sciences' Share-based Compensation history runs 6 years deep, the most recent figure standing at $269.0 million for Q4 2025.
- Quarterly Share-based Compensation rose 30.87% year-over-year to $269.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $627.5 million (up 34.07% YoY) and the FY2026 annual result came in at $346.2 million, up 19.77% from the prior year.
- Share-based Compensation was $269.0 million for Q4 2025 at Roivant Sciences, up from $70.8 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $487.8 million in Q4 2021 and bottomed at $44000.0 in Q1 2025.
- A 5-year average of $102.1 million and a median of $57.0 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation soared 3371.89% — and 2025, when it tumbled 96.62%.
- Roivant Sciences' Share-based Compensation stood at $487.8 million in 2021, then plunged by 60.54% to $192.5 million in 2022, then dropped by 20.57% to $152.9 million in 2023, then soared by 34.43% to $205.5 million in 2024, then soared by 30.87% to $269.0 million in 2025.
- Business Quant data shows ROIV's Share-based Compensation at $269.0 million in Q4 2025, $70.8 million in Q3 2025, and $82.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 269.00 Mn |
| Dec 31, 2025 | 269.00 Mn |
| Sep 30, 2025 | 70.83 Mn |
| Sep 30, 2025 | 70.83 Mn |
| Jun 30, 2025 | 82.18 Mn |
| Jun 30, 2025 | 82.18 Mn |
| Mar 31, 2025 | 44,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 205.54 Mn |
| Dec 31, 2024 | 205.54 Mn |
| Sep 30, 2024 | 59.44 Mn |
| Sep 30, 2024 | 59.44 Mn |
| Jun 30, 2024 | 50.19 Mn |
| Jun 30, 2024 | 50.19 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Dec 31, 2023 | 152.90 Mn |
| Dec 31, 2023 | 152.90 Mn |
| Sep 30, 2023 | 37.76 Mn |
| Sep 30, 2023 | 37.76 Mn |